Cytokinetics (CYTK) Reports Q2 Loss, Beats Revenue Estimates
Cytokinetics (CYTK) delivered earnings and revenue surprises of +7.98% and +40.20%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?